Company ProfilePremium

Arvee Laboratories (India) Ltd.

Company Profile Analysis

Ticker: ARVEE.NS

ESOMAR 23 Corporate BadgeISO Certifications Badge
Arvee Laboratories (India) Ltd. - Company showcase

Year Founded & Workforce

2012

65 Employees

Arvee Laboratories (India) Ltd. logo

Arvee Laboratories (India) Ltd. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Arvee Laboratories (India) Ltd. Overview

Arvee Laboratories is a Gujarat-based, promoter-controlled manufacturer of niche aromatic and heterocyclic fine chemicals, operating a single multi-purpose batch plant near Bhavnagar. Its portfolio spans three application families: sulfonated isophthalic "polymer modifiers" (sodium and lithium salts of 5-sulfoisophthalic acid and their esters) that impart cationic dyeability and water dispersibility to polyester fibres, films and resins; nitro-, amino- and hydroxy-isophthalic "contrast media intermediates" that sit upstream of iodinated X-ray/CT contrast agents; and thiophene- and pyridine-based "drug intermediates". The business is small (FY2026 revenue INR 31.5 crore), volatile (revenue has swung between INR 30 crore and INR 61 crore over four years), nearly debt-free, and increasingly export-oriented, with foreign-exchange earnings equal to roughly 28% of FY2026 revenue. A record Q1 FY2027 (revenue INR 17.2 crore) has re-rated the stock, but the company remains a thinly traded, uncovered nano-cap with a non-cooperating credit rating and limited disclosure.


What the company does

Arvee Laboratories manufactures and sells specialty and intermediate chemicals produced by multi-step batch synthesis. The company's own statutory description is brief: its FY2026 Board's Report states only that the company "is engaged in Chemicals" and that there has been no change in the nature of business. The segment note in its Q1 FY2027 results describes operations as falling within the chemicals business, now reported across two segments — a "Textile Chemical Segment (Films & Fibre)" and a "Non-textile Segment" (FY2026 integrated filing marked "Multi segment"; Q1 FY2027 segment table).

Data vendors that summarise its filings (Morningstar, Wright Research, Musaffa) characterise Arvee as a specialty chemical company organised around three product families — polymer modifiers, contrast media intermediates and drug intermediates — and note that it principally operates in India by location of assets, although its FY2026 foreign-exchange earnings show that a material share of sales is now exported.

Chemistry and manufacturing capability

The company's website lists the unit processes its Bhavnagar plant is equipped to run: nitration, sulfonation, reduction (including catalytic reduction), halogenation, esterification, alkylation, acylation, Hofmann reaction, Grignard reaction, Vilsmeier–Haack reaction, Sandmeyer reaction, caustic fusion and Friedel–Crafts reaction. Equipment disclosed on the website includes approximately 80,000 litres of glass-lined reactor capacity (individual vessels from 1 KL to 6.3 KL), approximately 35,000 litres of stainless-steel reactor capacity (0.5 KL to 6.5 KL), more than 8,500 litres of simultaneous centrifugation capacity, more than 6,000 litres of agitated Nutsche filtration capacity, stainless-steel distillation columns, and rotocone vacuum, fluidised-bed and tray dryers, supported by boilers, chilling and brine plants, cooling towers, power generation, DM water, vacuum systems and an effluent treatment plant.

This is the profile of a classic Indian "multi-purpose intermediates" plant: a modest total reactor volume (roughly 115 KL) that can be re-configured across many chemistries, which allows a broad catalogue but limits scale economics in any single molecule.

Business and revenue model

Revenue model componentAssessmentBasis
Product sales (manufactured goods)Essentially 100% of revenueAll reported revenue is "revenue from operations" from chemical sales; no service, licensing or subscription revenue is disclosed
Services / tolling / custom synthesis—The company's origins involved job-work arrangements (see Section 3), but no current tolling revenue is reported
Licensing / royaltiesNone disclosed—
SubscriptionNot applicable—
Other incomeINR 0.69 crore in FY2026 (about 2% of revenue)FY2026 Annual Report

Sales are business-to-business, made to manufacturers rather than end consumers. Pricing is not disclosed; as a commodity-linked intermediate producer, pricing is likely negotiated per order or per contract with exposure to input-cost pass-through, but this is an analytical inference, not a disclosed fact.

Value-chain position

Arvee sits in the middle of the chemical value chain. Upstream, it buys aromatic and heterocyclic feedstocks (isophthalic acid derivatives, thiophene, pyridine and related raw materials, plus acids, alkalis and solvents); its FY2026 foreign-exchange outgo on imported raw materials was INR 7.38 crore against total raw material consumption of INR 18.19 crore, implying that roughly 41% of materials consumed by value were imported (FY2026 Annual Report; analytical calculation). Downstream, its outputs are consumed by:

  • polyester fibre, film and resin producers (polymer modifiers for cationic-dyeable polyester, water-dispersible polyester, textile sizing, spin finishes);

  • manufacturers of iodinated contrast media active ingredients, through their intermediate supply chains (contrast media intermediates);

  • pharmaceutical API and advanced-intermediate manufacturers (drug intermediates);

  • per CRISIL, also customers in fertiliser and "other" industries.

Customer types and end-markets

End-marketProducts relevantDisclosure status
Textiles / polyester fibres and filmsDMS/Na-SIPA/Li-SIPA/SIPHE-40 polymer modifiersNamed application areas disclosed (prospectus, website); customer names not disclosed
Medical imaging (iodinated contrast agents)5-NIPA, DM-5-NIPA, MM-5-NIPA, 5-AIPA, dimethyl 5-AIPA, 5-HIPA, 3,5-DNBA, 3,5-diaminobenzoic acidApplication disclosed; customer names not disclosed
Pharmaceuticals2-acetylthiophene, thiophene-2-carboxaldehyde, 4-aminopyridine, 2-chloro-5-nitrobenzoic acidApplication disclosed; customer names not disclosed
Fertilisers and otherNot specifiedCRISIL description

Customer concentration: not publicly disclosed in the sources reviewed. Given the company's size and the niche nature of each molecule, meaningful concentration is likely, but no figures are published.

Independent characterisation

Arvee is best characterised as a sub-scale, owner-managed, multi-product intermediates manufacturer whose earnings are highly sensitive to a small number of orders and to working-capital swings. Its competitive "moat", to the extent one exists, lies in process know-how for a set of low-volume molecules (notably SIPA salts and nitro-isophthalic contrast-media precursors) where global buyer pools are concentrated and qualification cycles create some stickiness. Against that, there is no disclosed R&D spend, no patent portfolio, a single plant, and a revenue history that has gone sideways for nearly a decade (FY2016 revenue INR 26.8 crore; FY2026 revenue INR 31.5 crore; ten-year sales CAGR of about 2% per Screener).

Strategy

Stated corporate strategy

Arvee publishes no formal strategy document, investor presentation or medium-term plan, and holds no investor days or earnings calls. The only strategy-relevant statements found in disclosures are:

Mission themes (website): The company's tagline is "Delivering Quality, Thinking Safety, Preserving Nature", and its website describes an aspiration to be a leading chemical manufacturer offering good-quality, innovative products at competitive prices, with an eco-friendly orientation.

Diversification (prospectus-era, per IIFL summary): The promoters aimed to diversify into specialty chemicals such as dimethyl 5-nitroisophthalate, thiophene-2-carboxaldehyde, 2-acetylthiophene and lithium sulfoisophthalic acid (LiSIPA) serving Indian and overseas customers — products that are now in the catalogue.

FY2026 Board's Report: States that the company "is taking all the possible steps to increase the profitability" and, on dividends, that resources are being conserved. No specific initiatives are named.

Initiatives in the last 24 months

DateInitiativeStatus / detailSource
FY2025–FY2026Capex: net fixed assets rose from INR 12.67 crore (FY2024) to INR 16.72 crore (FY2026); implied capex ~INR 4.7 crore over two yearsNature of capex not disclosed (likely debottlenecking/maintenance)Screener
FY2026Export push: export receipts +40%; export sales commission nearly tripledImplies use of overseas agentsFY2026 Annual Report
FY2026Investment of INR 1.70 crore appears on balance sheet (first since FY2021)Nature not disclosedScreener
FY2026 / Q1 FY2027Segment re-organisation: two segments (Textile Films & Fibre vs Non-textile) introduced, with transfer of assets from Textile to Non-textileImplemented in Q1 FY2027 reportingQ1 FY2027 results
2026 (before 7 Aug)Scheme of Arrangement proposedOn 7 Aug 2026, the board "decided to postpone the Scheme of arrangement for better understanding of the matter". Nature (demerger, merger, capital reorganisation, etc.), counterparties and terms are not publicly disclosed in sources reviewedBoard outcome 7 Aug 2026
OngoingEnergy conservation: LED lighting installed; no alternative-energy or energy-capex initiativesFY2026 Board's ReportFY2026 Annual Report

Transformation, cost programmes, ESG commitments

None announced. No sustainability targets, cost-reduction programmes with numeric targets, or digital/platform investments have been disclosed.

Management guidance / medium-term targets

Not publicly disclosed. The company provides no revenue, margin or capex guidance.

Products & Services

The catalogue below is compiled from the company website product menu, the IPO prospectus (as summarised by Screener), and data-vendor descriptions. Specifications, launch years and pricing are not publicly disclosed for any product unless noted; target customers are described by application. Applications for polymer modifiers are as stated in the prospectus; other applications reflect well-established industry uses of these molecules.

Polymer Modifiers (likely mapped to Textile Chemical Segment)

ProductAbbreviationDescription / functionTarget customerLaunch yearPricing
Dimethyl 5-sodiosulfoisophthalateDMS salt (also DCBMS salt per prospectus)Sulfonated isophthalate ester co-monomer; introduces anionic sulfonate sites into polyester chains to make them dyeable with cationic (basic) dyesPolyester fibre and yarn producers——
5-Sulfoisophthalic acid monosodium saltNa-SIPAAcid-form co-monomer for cationic-dyeable polyester and water-dispersible polyester resinsPolyester fibre, resin and coating producers——
5-Sulfoisophthalic acid monolithium saltLi-SIPALithium analogue of SIPA, used where lithium counter-ion is preferred (e.g., certain polyester and specialty polymer formulations); prospectus also lists LiSIPA among diversification targetsPolyester / specialty polymer producers——
5-Sodiosulfo-bis-(β-hydroxyethyl)-isophthalateSIPHE-40Glycol ester (typically supplied as a solution) for direct incorporation into polyester polymerisationPolyester polymer producers——

Prospectus-listed applications for the family: cationic dyeability of polyester, water-soluble/dispersible polyester resins, textile sizing and coatings, and synthetic-fibre spin finishes.

Contrast Media Intermediates (likely mapped to Non-textile Segment)

ProductAbbreviationDescription / functionTarget customer
5-Nitroisophthalic acid5-NIPANitration product of isophthalic acid; key building block toward 5-aminoisophthalic acid derivatives used in iodinated contrast agentsContrast-media API makers and their intermediate suppliers
Dimethyl 5-nitroisophthalateDM-5-NIPAEsterified 5-NIPA; precursor to dimethyl 5-aminoisophthalateSame
Monomethyl 5-nitroisophthalateMM-5-NIPAMono-ester variant used in alternative synthetic routesSame
5-Hydroxyisophthalic acid5-HIPAHydroxylated isophthalic acid (also used in polymer and specialty applications)Contrast-media and specialty chemical makers
5-Aminoisophthalic acid5-AIPAReduction product of 5-NIPA; core scaffold for tri-iodinated benzene contrast agentsContrast-media API makers
Dimethyl 5-aminoisophthalateATIPA (website code)Ester of 5-AIPA; downstream intermediateContrast-media API makers
3,5-Dinitrobenzoic acid3,5-DNBADinitrated benzoic acid; precursor to 3,5-diaminobenzoic acidContrast-media and dye/pharma makers
3,5-Diaminobenzoic acid(ATIPA-CL page on website)Reduction product of 3,5-DNBA; a building block for diatrizoate-type contrast agents and specialty polymersContrast-media and polymer makers

Drug Intermediates (likely mapped to Non-textile Segment)

ProductDescription / functionTarget customerNote
2-AcetylthiopheneThiophene ketone used as a pharmaceutical building blockAPI / advanced-intermediate makersThiophene-derivative plant was the company's first, commissioned 2013
Thiophene-2-carboxaldehydeThiophene aldehyde used in pharmaceutical and agrochemical synthesisAPI makersSame plant lineage; prospectus listed it as a diversification focus
4-AminopyridinePyridine amine used as a pharmaceutical intermediate (and as an API in some markets)Pharmaceutical makers—
2-Chloro-5-nitrobenzoic acidHalogenated nitro-aromatic acid used as an intermediatePharma / dye makers—

Services

No services, toll manufacturing or custom synthesis offerings are separately marketed on the website or disclosed in filings. Not publicly disclosed.

Portfolio observations

The catalogue has been essentially static: the same 16 products appear in the 2018 prospectus summary and on the 2026 website. No new product launches have been announced in the last 24 months in any filing reviewed. The breadth (16 molecules across 3 families) relative to revenue (~INR 31–41 crore) implies average revenue per product of only about INR 2–2.5 crore, consistent with a niche, campaign-based batch producer.

Financial Narrative

Sources: Screener.in standardised standalone financials (data by C-MOTS, derived from company annual reports) for FY2022–FY2026; FY2025 and FY2026 Board's Reports; Q1 FY2027 results. Ratios marked "calc." are computed by the analyst from the reported figures. All figures INR crore unless stated.

Income statement

Notes:

  • Diluted EPS equals basic EPS; the company has no convertible instruments or ESOPs (FY2026 Annual Report). The company's own FY2026 results show EPS of INR 2.29, a rounding difference from Screener's INR 2.30.

  • FY2025 figures per the Board's Report: revenue INR 384,872 thousand, PBT INR 28,708 thousand, PAT INR 21,473 thousand. FY2026: revenue INR 315,141 thousand, PBT INR 24,304 thousand, tax credit INR 959 thousand, PAT INR 25,263 thousand.

Gross profit (where derivable)

Arvee does not report gross profit. A materials-based gross margin can be derived only where the full expense breakdown was retrieved:

FY2022–FY2025 gross profit: not publicly disclosed in the sources reviewed. The swing between FY2026 (inventory build of INR 3.5 crore credited to P&L) and Q1 FY2027 (inventory drawdown of INR 2.1 crore debited) shows that reported gross margin is heavily affected by inventory timing; a "true" run-rate gross margin likely lies between the two.

Margins and growth

Revenue CAGR FY2022–FY2026 (4 years, calc.): approximately −6.0% per year. Screener reports 5-year sales CAGR of −8% and 3-year of −20%, and TTM growth of +17%.

Commentary. The five-year record is one of high volatility around a flat-to-declining trend. FY2023 was an outlier year — revenue rose 52% to INR 61.35 crore and ROCE peaked at 23% — most plausibly driven by an unusually large order book in one or more product families (the company has not explained the spike in the materials reviewed). FY2024 then saw revenue halve to INR 30.35 crore, with EBITDA margins compressing below 10% as fixed costs were spread over a smaller base and the tax rate spiked to 42.6% (Q4 FY2024 alone carried an 81% tax rate on a small profit base). FY2025 recovered partially (+26.8%) on strong H1 sales (Q1 and Q2 FY2025 revenue of INR 10.6 crore and INR 12.5 crore), but the second half was weak, with Q4 FY2025 EBITDA margin at only 3.4%. FY2026 was a second down year (−18%), with Q2 FY2026 revenue collapsing to INR 3.45 crore — the lowest quarterly figure in at least three years — before a sharp H2 recovery.

Net income in FY2026 (+17.7%) outpaced pre-tax income (−15%) solely because of a net tax credit of INR 0.96 crore, driven by a deferred-tax credit of INR 0.47 crore and a Q3 FY2026 negative tax charge. Net margin of 8.0% in FY2026 is therefore flattered and should not be treated as a run-rate.

Depreciation has fallen from INR 2.3 crore to INR 1.2 crore over five years as older assets became fully depreciated, which has mechanically supported EBIT margins despite weaker EBITDA margins.

Quarterly trend (13 quarters)

(Source: Screener.in quarterly standalone data; Q1 FY2027 cross-checked to the company's 7 August 2026 filing: revenue INR 1,722.53 lakh, PBT INR 228.88 lakh, PAT INR 169.41 lakh, EPS INR 1.54.)

Inflection. The three most recent quarters show a clear upturn: revenue of INR 9.78 crore, INR 10.80 crore and INR 17.23 crore, with Q1 FY2027 the highest quarterly revenue in the 13-quarter window and the highest EBITDA (INR 2.49 crore). Q1 FY2027 revenue was up 130% YoY and 59% QoQ. Trailing-twelve-month (Q2 FY2026–Q1 FY2027) revenue is INR 41.26 crore and TTM net income INR 4.05 crore (EPS about INR 3.67). However, Q1 FY2027 cost structure shows a INR 2.08 crore inventory drawdown, meaning part of the revenue surge was met from stock built in FY2026 rather than new production; sustainability will depend on order inflows in Q2 and Q3 FY2027.

Balance sheet

Notes and gaps:

  • Goodwill and intangibles: none disclosed (no acquisitions accounted for as business combinations).

Short-term vs long-term debt split: not disclosed in the standardised data. CRISIL's rating covers INR 5.50 crore of cash credit (short-term working capital), INR 4.06 crore of term loan and INR 4.44 crore of proposed long-term facilities — these are sanctioned limits, not outstanding balances. Outstanding borrowings were only INR 1.11 crore at 31 March 2026.

Cash & equivalents, net debt, working capital: cash balances were not disclosed in the sources reviewed, so net debt and precise working capital cannot be computed.

  • Other equity at 30 June 2026 was INR 24.46 crore (Q1 FY2027 filing), taking net worth to about INR 35.6 crore (book value ~INR 32.3 per share; Screener shows INR 30.7 based on 31 March 2026).

  • FY2026 retained earnings rose from INR 18.31 crore to INR 20.83 crore; securities premium was unchanged at INR 1.94 crore (FY2026 Board's Report).

Cash flow

Commentary. Cash conversion is the weakest part of the financial profile. Over FY2022–FY2026, cumulative net income was INR 12.4 crore but cumulative operating cash flow only INR 6.9 crore and cumulative free cash flow −INR 4.2 crore. In FY2025 and FY2026 combined, the company reported INR 4.7 crore of profit but negative operating cash flow, as receivables and inventory absorbed cash (debtor days rose from 73 to 121; inventory days from 80 to 229 between FY2025 and FY2026). The positive FY2026 investing cash flow (+INR 0.50 crore) despite ~INR 2.8 crore of capex suggests asset or investment disposals/other investing inflows, but the breakdown was not disclosed in the materials reviewed. Financing outflows since FY2022 have been minimal, reflecting completion of the deleveraging that began in FY2019.

Ratios

Not computable from sources reviewed: current ratio and net debt / EBITDA (cash and current-asset/current-liability splits not disclosed). ROIC is not reported; ROCE is used as a proxy.

Commentary. Returns are mediocre outside FY2023: average ROE across FY2024–FY2026 is about 6%, below any reasonable cost of equity for an illiquid nano-cap. Leverage is negligible and interest coverage comfortable. The single most important negative trend is the deterioration in the cash conversion cycle, which has more than quadrupled from 42 days (FY2023) to 191 days (FY2026). Some of this is the arithmetic effect of a revenue dip on year-end balances, and Q1 FY2027's inventory drawdown suggests partial reversal is under way, but the trend warrants close monitoring.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment Overview

SegmentWhat it contains (analyst mapping)Products (analyst mapping; company does not publish a product-to-segment map)

Textile Chemical Segment (Films & Fibre)

Polymer modifiers sold into polyester fibre and film applications

DMS salt, Na-SIPA, Li-SIPA, SIPHE-40 (likely)

Non-textile Segment

Contrast media intermediates, drug intermediates and other non-textile chemicals

5-NIPA family, 5-AIPA family, 5-HIPA, 3,5-DNBA, 3,5-diaminobenzoic acid, thiophene derivatives, 4-aminopyridine, 2-chloro-5-nitrobenzoic acid

Metric (INR Lakh, Q1 FY2027, Quarter Ended 30 Jun 2026) Details

Metric (INR Lakh, Q1 FY2027, quarter ended 30 Jun 2026)Textile (Films & Fibre)Non-textileTotal

Segment revenue (incl. other income)

230.581,510.031,740.61

Share of total revenue

13.2%86.8%100%

Segment result (PBIT)

29.99204.96234.95

Segment PBIT margin

13.0%13.6%13.5%

Capital employed

422.803,154.803,577.60

Annualised segment pre-tax return on capital employed (analyst calc., ×4)

28.4%26.0%26.3%

Segment revenue (INR Cr)

Segment revenue (INR Cr)FY2024FY2025FY2026

Total revenue from operations

30.3538.4931.51

Income Statement and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Revenue from operations (INR Cr)

40.3361.3530.3538.4931.51

Total operating expenses (INR Cr)

34.6554.0627.4134.8828.33

EBITDA excl. other income (INR Cr)

5.687.292.943.613.18

Other income (INR Cr)

0.461.350.640.660.69

Depreciation (INR Cr)

2.322.081.501.151.21

Operating income EBIT incl. other income (INR Cr, calc.)

3.826.562.083.122.66

Interest expense (INR Cr)

0.370.390.250.250.23

Pre-tax income (INR Cr)

3.456.171.832.872.43

Effective tax rate (%)

25.5133.2342.6225.09-3.70

Net income (INR Cr)

2.574.121.052.152.53

EPS basic (INR)

2.333.740.951.952.30

EPS diluted (INR)

2.333.740.951.952.30

Dividend per share (INR)

00000

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Revenue History

PeriodRevenue (INR Lakh)Cost of materials consumed (INR Lakh)Change in inventories (INR Lakh)Materials gross profit (INR Lakh, calc.)Materials gross margin

FY2026

3,151.411,818.90-352.531,685.0453.5%

Q1 FY2027

1,722.53916.64207.83598.0634.7%

Q1 FY2026

748.00548.27-206.34406.0754.3%

Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

EBITDA margin excl. other income (%)

14.0811.889.699.3810.09

EBIT margin incl. other income (%, calc.)

9.4710.696.858.118.44

Pre-tax margin (%, calc.)

8.5510.066.037.467.71

Net margin (%, calc.)

6.376.723.465.598.03

Revenue growth YoY (%, calc.)

-14.8852.12-50.5326.82-18.13

Net income growth YoY (%, calc.)

-4.1060.31-74.51104.7617.67

Income Statement and Margin Analysis (%) (Quarterly)

MetricQ1FY24Q2FY24Q3FY24Q4FY24Q1FY25Q2FY25Q3FY25Q4FY25Q1FY26Q2FY26Q3FY26Q4FY26Q1FY27

Revenue (INR Cr)

7.608.917.706.1410.6012.538.916.457.483.459.7810.8017.23

EBITDA excl. other income (INR Cr)

0.980.690.530.791.541.500.340.220.340.121.631.102.49

EBITDA margin (%)

12.897.746.8812.8714.5311.973.823.414.553.4816.6710.1914.45

Pre-tax income (INR Cr)

0.650.280.320.581.261.310.200.090.180.011.400.862.29

Net income (INR Cr)

0.490.210.240.120.940.980.150.070.170.011.830.521.69

EPS (INR)

0.440.190.220.110.850.890.140.060.150.011.660.471.53

Balance Sheet

MetricFY2022FY2023FY2024FY2025FY2026

Equity share capital (INR Cr)

11.0211.0211.0211.0211.02

Reserves / other equity (INR Cr)

12.9217.0418.0920.2422.77

Total shareholders' equity (INR Cr)

23.9428.0629.1131.2633.79

Total borrowings (INR Cr)

3.131.001.001.031.11

Other liabilities (INR Cr)

11.619.638.455.297.99

Total assets (INR Cr)

38.6838.6938.5637.5842.89

Net fixed assets (INR Cr)

13.8412.6812.6715.2716.72

Capital work in progress (INR Cr)

0.981.532.620.730.90

Investments (INR Cr)

00001.70

Other assets incl. current assets (INR Cr)

23.8624.4823.2721.5823.57

Goodwill & intangibles (INR Cr)

00000

Cash Flow and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Cash from operating activities (INR Cr)

0.682.933.66-0.21-0.12

Cash from investing activities (INR Cr)

0.06-1.26-2.16-1.320.50

Cash from financing activities (INR Cr)

-6.06-2.42-0.19-0.12-0.16

Net cash flow (INR Cr)

-5.32-0.751.31-1.640.23

Implied capex (INR Cr, CFO minus FCF)

2.361.462.591.852.83

Free cash flow (INR Cr)

-1.681.471.07-2.06-2.95

Dividends paid (INR Cr)

00000

Share buybacks (INR Cr)

00000

CFO / EBITDA (%)

2964139103

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2022FY2023FY2024FY2025FY2026

ROE on average equity (%, calc.)

11.315.83.77.17.8

ROA on average assets (%, calc.)

6.410.72.75.66.3

ROCE (%, Screener; proxy for ROIC)

12.8923.346.839.587.53

Debt / equity (x, calc.)

0.130.040.030.030.03

Gross debt / EBITDA (x, calc.)

0.550.140.340.290.35

Interest coverage EBIT / interest (x, calc.)

10.316.88.312.511.6

Asset turnover on average assets (x, calc.)

1.011.590.791.010.78

Debtor days

109.7872.9473.4879.66121.05

Inventory days

93.2442.29159.0280.31228.81

Payable days

160.1273.30164.4957.72159.35

Cash conversion cycle (days)

42.9041.9468.01102.25190.51

Working capital days

49.9670.4495.97103.55168.43

Revenue by Region

Geography (INR Cr, cash-basis proxy)FY2025FY2026

Export receipts (foreign exchange earnings)

6.268.75

Domestic revenue (derived: revenue less export receipts)

32.2322.76

Total revenue from operations

38.4931.51

Export receipts as % of revenue

16.327.8

Revenue by Region by Outflow

Outflow (INR Cr)FY2025FY2026

Imported raw materials

7.577.38

Export sales commission

0.080.22

Valuation Snapshot

MetricValueSource

Last close (19 Oct 2026)

INR 209 (−7.48% on the day)

Screener

52-week high / low

INR 291 / INR 129

Screener

1-year price CAGR

~30%

Screener (19 Oct 2026)

3-year price CAGR

~22%

Screener

5-year price CAGR

~19%

Screener

IPO price (Feb 2018)

INR 61 (≈INR 30.5 bonus-adjusted); current price ≈6.9x bonus-adjusted IPO price

IPO records; calc.

Historical 5-year high

~INR 315 (per Equentis, as of Apr 2026)

Equentis

Valuation Multiples

MultipleArveeBasis

Market capitalisation

INR 231 crore

1.102 crore shares × INR 209

P/E (TTM)

~56.9x

TTM EPS ~INR 3.67 (Screener)

P/E (FY2026 EPS INR 2.30)

~91x

calc.

P/B

~6.8x

Book value INR 30.7 per share at 31 Mar 2026 (Screener)

EV (approx.)

~INR 232 crore upper bound

Market cap + debt INR 1.11 crore; cash not disclosed (would reduce EV)

EV/Sales (TTM)

~5.6x

TTM revenue INR 41.26 crore

EV/EBITDA (TTM)

~43x

TTM EBITDA INR 5.34 crore

Dividend yield

0%—

Peer median P/E / P/B (Value Research, Apr 2026)

~36.7x / ~2.2x

Value Research

Capital Markets

MetricFY2022FY2023FY2024FY2025FY2026

Dividend per share (INR)

00000

Dividend payout (%)

00000

Action by Date

DateActionDetail

22 Feb 2018

IPO / listing

14.6 lakh shares at INR 61; NSE Emerge

13–15 Oct 2020

Bonus issue 1:1

55.10 lakh bonus shares allotted; capital INR 5.51 crore → INR 11.02 crore

FY2021–FY2022

Migration to NSE Main Board

Board approval 10 Oct 2020

Credit Ratings

AgencyRatingOutlookInstrumentsDateNote

CRISIL Ratings

B-

Stable

INR 14 crore long-term bank facilities: cash credit INR 5.50 crore; term loan INR 4.06 crore; proposed long-term facility INR 4.44 crore

27 Feb 2026 (also 27 Dec 2024, 31 Oct 2023)

"Issuer Not Cooperating" — rating based on best-available information; company did not provide information or No Default Statements despite repeated requests

Moody's / S&P / Fitch

Not rated

————

Analyst Conclusions

Management guidance

None provided. No earnings calls, investor presentations or quantitative guidance exist.

Consensus expectations

None available (no coverage).

Bull case

  1. Earnings inflection is real and operating leverage is high. Revenue rose sequentially for three quarters to a record INR 17.23 crore in Q1 FY2027, with PBT of INR 2.29 crore — more than the entire FY2024 PBT (INR 1.83 crore). If even half of Q1's run-rate persists, FY2027 could deliver the company's best year since FY2023.

  2. Export mix shift improves quality of demand. Export receipts grew 40% in FY2026 to ~28% of revenue while domestic sales shrank; export-led growth in qualification-gated contrast-media and pharma intermediates may be stickier than domestic textile demand.

  3. Balance-sheet optionality. With near-zero debt, INR 33.8 crore of equity and the INR 3.5 crore inventory build of FY2026 now unwinding, working-capital release could fund growth capex or the proposed restructuring without dilution.

Bear case

  1. History of mean reversion. FY2023's record was followed by a 50% revenue collapse; Q1–Q2 FY2025 strength was followed by a weak H2. Q1 FY2027 was partly served from inventory (INR 2.08 crore drawdown), so production-backed demand may be lower than headline revenue implies.

  2. Cash does not follow profits. Two consecutive years of negative operating cash flow and a 191-day cash conversion cycle mean reported earnings have not translated into shareholder cash; no dividends have ever been paid.

  3. Valuation and governance discount not reflected. At ~57x TTM earnings and ~6.8x book — well above the specialty-chemicals peer medians of ~37x and ~2.2x — the stock prices in sustained growth from a company with zero R&D, a single plant, a static catalogue, non-cooperation with its credit rater, recent listing-compliance lapses and an unexplained, postponed restructuring.

Key catalysts and monitorables (next 12 months)

#Catalyst / monitorableTimingWhat to watch
1Q2 FY2027 results3 Nov 2026Whether revenue holds above INR 10 crore and margins above 12%; segment split trend
2Q3 FY2027 results~Feb 2027Sustainability of the recovery beyond one strong quarter
3Scheme of ArrangementUndeterminedRevival, terms, nature (demerger/merger), valuation and minority-shareholder impact
4Working capitalH1 FY2027 balance sheet (Nov 2026)Reduction in inventory and receivable days; CFO turning positive
5CRISIL engagementNext review (~late 2026/early 2027)Whether the company cooperates and the INC tag is removed
6Export disclosuresFY2027 Annual ReportExport share, destination markets, customer additions
7Compliance recordOngoingAbsence of further NSE fines or late disclosures
8Capex / capacityOngoingAny announced expansion, new molecules or R&D investment
9Related-party transactionsFY2027 Annual Report (note 35)Magnitude of rent, consultancy and purchase transactions with promoter entities
10Share liquidityOngoingShareholder base growth; any institutional entry

Analyst verdict

Arvee Laboratories is a genuine but very small specialty-intermediates manufacturer whose investment case rests almost entirely on whether its recent operating upturn is durable. The positives are tangible: a versatile multi-chemistry plant, a debt-free balance sheet, a portfolio of qualification-gated contrast-media and pharmaceutical intermediates, an export business that grew 40% last year, and a record Q1 FY2027 in which a single quarter generated more pre-tax profit than all of FY2024. Operating leverage is evident — when volumes arrive, incremental margins are high.

The negatives, however, are structural rather than cyclical. Revenue in FY2026 was lower than in FY2018; the product catalogue has not changed in eight years; R&D spending is reported as nil; and the business has repeatedly followed strong periods with sharp reversals. Earnings have not converted into cash for two consecutive years, the cash conversion cycle has stretched to roughly six months, and no dividend has ever been paid. Governance and disclosure fall short of institutional standards: the company does not cooperate with its credit-rating agency, received a secretarial audit observation and an NSE fine within the last year, publishes internally inconsistent segment and committee disclosures, transacts routinely with promoter-owned entities, and has proposed — then postponed without explanation — a Scheme of Arrangement whose terms remain undisclosed.

At roughly 57 times trailing earnings and nearly seven times book value, the market is already capitalising a sustained recovery. For that valuation to be justified, Arvee would need to show at least three further quarters of revenue above INR 10 crore with positive operating cash flow, clarify the restructuring, and improve disclosure. Until such evidence emerges, the stock is best regarded as a high-risk, event-driven nano-cap.


APPENDIX A — LONG-RUN HISTORICAL SERIES (FY2016–FY2021)

MetricFY2016FY2017FY2018FY2019FY2020FY2021
Revenue (INR Cr)26.8234.4447.7854.9045.4247.38
EBITDA excl. other income (INR Cr)4.995.907.176.176.026.07
EBITDA margin (%)18.6117.1315.0111.2413.2512.81
Interest (INR Cr)3.073.483.331.630.990.58
Pre-tax income (INR Cr)0.530.861.922.543.093.64
Net income (INR Cr)0.191.551.092.262.302.68
Borrowings (INR Cr)25.3224.9916.1512.873.878.88
Shareholders' equity (INR Cr)2.644.2014.2016.4618.7621.44
ROCE (%)—15.1917.6413.6714.9014.92

(Source: Screener.in standalone data; equity = equity capital + reserves.) The early history shows a highly leveraged start-up phase (borrowings ~10x equity in FY2016) followed by IPO-funded and cash-flow-funded deleveraging through FY2020. EBITDA margins have trended down from ~18–19% in FY2016 to ~9–10% in FY2024–FY2026, indicating structural pricing or mix pressure.

APPENDIX B — RELATED-PARTY TRANSACTIONS DISCLOSED (FY2026 AOC-2)

Related partyRelationshipNature of transactionValue
Bharatbhai ChokshiFather of former co-promoter Shalin Chokshi; family holds ~36.74%Consultancy services to the companyPer note 35 of FY2026 financials
Kavita Shalin ChokshiWife of Shalin ChokshiRent of immovable property (11 months 29 days)Per note 35
Shalin Patel HUFMD is KartaRent of immovable propertyPer note 35
Arvee Speciality Chemicals Pvt Ltd100% owned by Patel and Chokshi families; MD is a directorRent of immovable propertyPer note 35
B Chokshi Chem Pvt Ltd100% owned by relatives of Shalin ChokshiPurchase of goodsPer note 35
Praveenkumar Rameshchandra MishraNon-executive directorConsultancy servicesPer note 35
Archana Praveenkumar MishraRelative of director P. R. MishraConsultancy servicesPer note 35

All transactions are stated by the company to be in the ordinary course of business, at arm's length, approved by the Audit Committee, and not material under SEBI LODR Regulation 23.

APPENDIX C — SOURCES CONSULTED

  • Arvee Laboratories (India) Ltd, Annual Report FY2025–26 (incl. AGM Notice, Board's Report, Secretarial Audit, Corporate Governance Report), filed with NSE 3 Sep 2026 — archives.nseindia.com

  • Arvee Laboratories, Outcome of Board Meeting and Unaudited Results for quarter ended 30 June 2026 (7 Aug 2026), incl. segment table and limited review by Nirav Patel & Associates — nsearchives.nseindia.com

  • Arvee Laboratories, Results for half-year ended 30 Sep 2025 (14 Nov 2025) — nsearchives.nseindia.com

  • NSE integrated filings (Ind AS) for FY2025 (9 May 2025) and FY2026 (19 May 2026); prior intimations (3 Feb 2025; 3 May 2026) — nsearchives.nseindia.com

  • NSE circulars on 1:1 bonus issue (7 Oct 2020; 20 Oct 2020) and company bonus/migration filings (24 Aug, 6 Oct, 10 Oct, 15 Oct 2020); re-appointment filing (27 Jun 2022)

  • CRISIL Ratings rationale, 27 Feb 2026 — crisil.com

  • Screener.in company page for ARVEE (financials, ratios, shareholding, announcements), accessed 19 Oct 2026

  • Business Standard / Capital Market, Q4 FY2025 results report (10 May 2025)

  • MoneyWorks4Me, Q4 FY2025 results summary

  • Goodreturns, FY2025 Directors' Report extract

  • IIFL (indiainfoline.com), company summary and board meeting history

  • IPO Central, Chittorgarh, IPO Platform, Samco — IPO details (Feb 2018)

  • Company website www.arveelabs.com (home, infrastructure, product pages)

  • Morningstar, Investing.com, Value Research, Wright Research, Musaffa, Research360, Equentis, IndMoney, Fyers, Torus Digital — market data and profiles

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleDINOn board sinceBackground / education / ageShares held (31 Mar 2026)FY2026 board attendanceSource

Shalin Sudhakarbhai Patel

Chairman & Managing Director; Promoter; Executive

01,779,902

Promoter in control since 1 Apr 2013; MD re-appointed 27 Jun 2022

Co-founder/promoter; also director on Shree Rama Multi-Tech Limited (member of its audit and stakeholders committees). Education and age not disclosed in sources reviewed

40,42,000 (36.68%)

5/5

FY2026 Annual Report

Saurin Ajitbhai Gandhi

Director (Non-Executive, Non-Independent per Corporate Governance report) and Chief Financial Officer

11,237,690

12 Aug 2025 (additional director); confirmed at AGM 24 Sep 2025; re-appointed on rotation at AGM 29 Sep 2026

M.Com (Accounts & Finance), Gujarat University; ~16 years' experience in accounts, finance and liaison; born 23 Aug 1983 (age 43)

4,000

2/2

FY2026 AGM Notice

Praveen Kumar Rameshchandra Mishra

Non-Executive, Non-Independent Director

10,687,679

Not stated in sources reviewed (DIN series suggests 2024 appointment)

Not disclosed; provides consultancy services to the company (related-party transaction)

0

5/5

FY2026 Annual Report

Sachin Kanwarlal Kansal

Independent Director; Chair of Audit Committee

03,566,139

1 Oct 2021; re-appointed for second term 1 Oct 2026 – 30 Sep 2031

B.Com, Chartered Accountant; experience in accounts, taxation, legal and administration; born 13 Sep 1987 (age 39)

0

5/5

FY2026 AGM Notice

Shalini Hitesh Jalan

Independent Director

09,620,065

26 May 2022; re-appointed for second term 26 May 2027 – 25 May 2032

B.A.; experience in computers; born 30 Sep 1982 (age 44); also director of Aprameya Engineering Limited (NSE-listed) and Air Control Chemical and Engineering Company Limited

0

5/5

FY2026 AGM Notice

Neetu Rishi Jalan

Independent Director; Audit Committee member

08,719,470

Not stated in sources reviewed

Not disclosed; holds one other listed directorship

0

5/5

FY2026 Annual Report

Shalin Bharat Chokshi (former)

Whole-Time Director; Co-Promoter

00,191,903

Promoter in control since 1 Apr 2013; ceased 30 Jun 2025

Co-founder/promoter; family continues to hold ~36.7%

0 (personally, at 31 Mar 2026)

2/5

FY2026 Annual Report

Governance Detail

RoleNameNote

Managing Director / Chairman

Shalin Sudhakarbhai Patel

Combined Chair and MD

Chief Financial Officer

Saurin Ajitbhai Gandhi

Also a board director

Company Secretary & Compliance Officer

Not identified in the excerpts reviewed

—

“—” = not publicly disclosed.

Executive Leadership Team

PersonComponentAmountSource

Saurin Ajitbhai Gandhi

Remuneration last drawn

INR 1,512 thousand (INR 15.12 lakh)

FY2026 AGM Notice

Sachin Kanwarlal Kansal

Remuneration / sitting fees last drawn

INR 70 thousand

FY2026 AGM Notice

Shalini Hitesh Jalan

Remuneration / sitting fees last drawn

INR 70 thousand

FY2026 AGM Notice

Shalin Sudhakarbhai Patel (MD)

Salary / bonus / stock / total

——

Board & Management Changes

DateChangeContext

30 Jun 2025

Shalin Bharat Chokshi (co-promoter, WTD) resigned

Ends dual-promoter executive leadership; Chokshi family retains its ~36.7% stake and continues to transact with the company (consultancy by Bharatbhai Chokshi; rent from Kavita Chokshi; purchases from B Chokshi Chem Pvt Ltd). Secretarial audit flagged late disclosure of the resignation

12 Aug 2025

Saurin Gandhi joined board

Adds finance capability; he is also CFO

29 Sep 2026

Re-appointment of Sachin Kansal (from 1 Oct 2026) and Shalini Jalan (from 26 May 2027) for second terms approved at AGM

Continuity of independent directors

Shareholding Trend

Holder categorySep 2024Mar 2025Sep 2025Mar 2026Sep 2026

Promoters & promoter group (%)

73.5073.5073.5073.5073.50

Public (%)

26.5026.5026.5026.5026.50

FIIs (%)

00000

DIIs / mutual funds (%)

00000

Number of shareholders

1,4161,5761,5051,6381,947

Competitive Landscape

Competitors by Segment

Product familyCompetitor set (analyst identification)Basis of overlap

Polymer modifiers (SIPA salts, DMS, SIPHE)

Chinese SIPA/DMS producers (individually small, numerous); other Indian specialty chemical makers of sulfonated aromatics; captive production by large polyester integrators

Same molecules; commodity-like pricing set largely by Chinese supply

Contrast media intermediates (5-NIPA, 5-AIPA, DNBA, DABA families)

Chinese and Indian contrast-media intermediate producers; captive/affiliated supply chains of the major iodinated contrast-agent originators (GE HealthCare, Bayer, Bracco, Guerbet are the principal global contrast-agent companies)

Upstream of iodinated contrast APIs (iohexol, iopamidol, iodixanol, diatrizoate class)

Drug intermediates (thiophenes, 4-aminopyridine, nitro-chlorobenzoic acids)

Jubilant Ingrevia (major pyridine and pyridine-derivative producer); Aarti Industries (nitro-aromatics, benzenoids); Hikal, Ami Organics, Laxmi Organic and similar Indian intermediate/CDMO players; Chinese thiophene derivative producers

Overlapping chemistries and customer base (Indian API makers)

Key Competitors

#CompanyListingRelevance to Arvee
1

Jubilant Ingrevia Ltd

NSE/BSE

Pyridine and pyridine derivatives (overlap with 4-aminopyridine)

2

Aarti Industries Ltd

NSE/BSE

Large nitration and reduction-chemistry platform (overlap with nitro-aromatic intermediates)

3

Hikal Ltd

NSE/BSE

Pharma intermediates / CDMO

4

Ami Organics Ltd

NSE/BSE

Advanced pharma intermediates

5

Laxmi Organic Industries Ltd

NSE/BSE

Specialty intermediates

6

Vinati Organics Ltd

NSE/BSE

Niche aromatic specialty chemicals and polymer additives (model of a niche-molecule leader)

7

GE HealthCare / Bayer / Bracco / Guerbet

Various

Principal global iodinated contrast-agent producers — ultimate demand setters (and potential captive competitors) for contrast intermediates

8

Chinese SIPA/DMS and nitro-isophthalic producers (unnamed)

Various

Price-setting competitors in polymer modifiers and contrast intermediates

9

Other Gujarat-based SME intermediates makers

Various

Similar scale and chemistry

10

Captive production by large polyester integrators

Various

Potential self-supply of SIPA/DMS

Competitor Detail

MetricArvee Laboratories

Revenue FY2026

INR 31.5 crore

Revenue growth FY2026

−18.1%

EBITDA margin FY2026

10.1%

Net margin FY2026

8.0% (tax-credit aided)

R&D intensity FY2026

0% (Nil reported)

P/E (Oct 2026)

~57x TTM

Company Snapshot

$3.6M

Revenue

65

Employees

2012

Founded

Ahmedabad, India

Headquarters

SWOT Analysis

Strengths

  • Negligible leverage: Borrowings of INR 1.11 crore against equity of INR 33.79 crore at 31 March 2026 (D/E ~0.03x); interest coverage ~11.6x in FY2026 (Screener; calc.).
  • Demonstrated capacity for high-margin quarters: EBITDA margins of 14.5% (Q1 FY2025), 16.7% (Q3 FY2026) and 14.5% (Q1 FY2027) (Screener).
  • Recovering top line: Three consecutive quarters of sequential revenue growth to a record INR 17.23 crore in Q1 FY2027 (+130% YoY) (Q1 FY2027 filing).
  • Growing export franchise: Foreign-exchange earnings up 40% to INR 8.75 crore in FY2026, ~28% of revenue (FY2026 Annual Report).
  • Versatile plant: ~115 KL of glass-lined and stainless-steel reactors capable of 14 named unit processes (company website).
  • Aligned, stable ownership: Promoters hold 73.5% with zero pledges, unchanged since listing (Screener; Research360).
  • Healthy segment returns (latest quarter): Annualised segment PBIT/capital employed of ~26% in Q1 FY2027 (calc. from Q1 FY2027 segment table).

Weaknesses

  • Very poor cash conversion: CFO negative in FY2025 (−INR 0.21 crore) and FY2026 (−INR 0.12 crore) despite cumulative PAT of INR 4.7 crore; FCF −INR 2.95 crore in FY2026 (Screener).
  • Ballooning working capital: Cash conversion cycle rose from 42 days (FY2023) to 191 days (FY2026); inventory days 229 (Screener).
  • Zero R&D: Nil R&D expenditure and Nil technology absorption reported for FY2026 (FY2026 Board's Report).
  • Revenue volatility and stagnation: FY2026 revenue (INR 31.5 crore) below FY2018 (INR 47.8 crore); 5-year sales CAGR −8% (Screener).
  • Low returns: 3-year average ROE ~6% (Screener); ROCE 7.5% in FY2026.
  • Disclosure and compliance lapses: CRISIL "Issuer Not Cooperating" since at least 2023; late disclosure of director resignation (FY2026 secretarial audit); NSE fine for Reg. 44 non-compliance (15 Oct 2026); inconsistent segment and committee disclosures within filings.
  • Earnings quality: FY2026 PAT exceeded PBT owing to a INR 0.96 crore net tax credit (FY2026 Board's Report).

Opportunities

  • Contrast-media supply diversification by global originators after past supply disruptions could favour qualified Indian intermediate suppliers (industry context; Arvee's 8-product contrast-media portfolio).
  • Export scale-up: Export commissions nearly tripled in FY2026 (INR 0.08 crore to INR 0.22 crore), indicating active channel building (FY2026 Annual Report).
  • Operating leverage: Q1 FY2027 PBT of INR 2.29 crore on INR 17.2 crore revenue versus INR 0.18 crore on INR 7.5 crore a year earlier shows high incremental margins (Q1 filings).
  • Corporate restructuring: The postponed Scheme of Arrangement and new segment reporting could unlock value or sharpen focus if completed (7 Aug 2026 board outcome).
  • Working-capital release: Q1 FY2027 inventory drawdown of INR 2.08 crore suggests FY2026's inventory build can convert to cash (Q1 FY2027 filing).
  • Main-board liquidity: Shareholder count up from 1,298 (Mar 2024) to 1,947 (Sep 2026), broadening the investor base (Screener).

Threats

  • Chinese price competition in commodity-like intermediates such as SIPA/DMS (industry structure).
  • Customer concentration (undisclosed but likely), as evidenced by quarter-to-quarter revenue swings from INR 3.45 crore to INR 17.23 crore (Screener).
  • Single-site operational/regulatory risk: All production at one Bhavnagar plant subject to Environment Protection, Air and Water Acts and Hazardous Waste Rules (FY2026 secretarial audit list of applicable laws).
  • Raw-material import and FX exposure: INR 7.38 crore of imported raw materials in FY2026 (FY2026 Annual Report).
  • Credit-access constraints: CRISIL B-/Stable (INC) rating on INR 14 crore of facilities may constrain bank funding for growth (CRISIL, Feb 2026).
  • Valuation risk: Stock at ~57x TTM P/E and ~6.8x book versus peer medians of ~37x and ~2.2x (Screener; Value Research), with a 52-week range of INR 129–291.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateApproachDevelopment
other than the NSE fineContract wins, layoffs/hiring, litigation and regulatory actionsnone disclosed in the period.

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

3 charts
Income Statement: Revenue & Gross Profit: Revenue from operations fell from INR 403.3 Mn in FY2022 to INR 315.1 Mn in FY2026.
Arvee Laboratories (India) Ltd. — Income Statement: Revenue & Gross Profit
Series (INR Mn)FY2022FY2023FY2024FY2025FY2026
Revenue from operations403.3613.5303.5384.9315.1

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.